ALKS 8-K 2026-09-21
Alkermes plc. (ALKS) 8-K dated 2026-09-21 — accession 0001193125-26-396065.
Alkermes plc. (ALKS) is a drug manufacturers - specialty & generic company listed on US.
Alkermes plc. filed a 8-K on 2026-09-21. Accession 0001193125-26-396065.
This 8-K covers: Reg FD disclosure (Item 7.01), Other events (Item 8.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported ALKS revenue for 2025-12-31 was $1.48B. Net income was $241.7M. Revenue was down 5.2% from 2024-12-31 to 2025-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 118.3.
Not investment advice. The ALKS SEC hub lists recent forms. The stock page is the research view.